Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
企業コードRDY
会社名Dr Reddy's Laboratories Ltd
上場日Jan 01, 1986
最高経営責任者「CEO」Mr. Deepak Sapra
従業員数27811
証券種類Ordinary Share
決算期末Jan 01
本社所在地8-2-337, Road No.3 Banjara Hills
都市HYDERABAD
証券取引所Australian Stock Exchange Ltd
国India
郵便番号500034
電話番号914049002900
ウェブサイトhttps://www.drreddys.com/
企業コードRDY
上場日Jan 01, 1986
最高経営責任者「CEO」Mr. Deepak Sapra
過去5年間の配当金総支払額は
332.70M
米ドルである。
RDY.NB Final Cash Dividend of gross USD 0.476153 paid on Aug 12, 2024 going ex on Jul 30, 2024
RDY.NB Final Cash Dividend of gross USD 0.482608 paid on Aug 11, 2023 going ex on Jul 28, 2023
RDY.NB Final Cash Dividend of gross USD 0.378434 paid on Aug 12, 2022 going ex on Aug 01, 2022
RDY.NB Final Cash Dividend of gross USD 0.336485 paid on Aug 11, 2021 going ex on Jul 30, 2021
RDY.NB Final Cash Dividend of gross USD 0.333364 paid on Aug 17, 2020 going ex on Jul 10, 2020